These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 198286)

  • 21. Endurance of immunity against foot-and-mouth disease in cattle after three consecutive annual vaccinations.
    Terpstra C; Van Maanen C; Van Bekkum JG
    Res Vet Sci; 1990 Sep; 49(2):236-42. PubMed ID: 2173088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Buffalo in the northern Natal game parks show no serological evidence of infection with foot-and-mouth disease virus.
    Esterhuysen JJ; Thomson GR; Flammand JR; Bengis RG
    Onderstepoort J Vet Res; 1985 Jun; 52(2):63-6. PubMed ID: 2995896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-reactions of normal bovine serums to foot-and-mouth disease virus in plaque-reduction neutralization and radial immunodiffusion.
    Andersen AA
    Am J Vet Res; 1975 Jul; 36(7):979-83. PubMed ID: 167625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross reactions of normal bovine sera with foot-and-mouth disease virus: incidence, duration, and effect of shipping stress.
    Andersen AA
    Am J Vet Res; 1978 Apr; 39(4):603-6. PubMed ID: 206170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative biochemical and serological analysis of five isolates of a single serotype of foot-and-mouth disease virus.
    Robson KJ; Crowther JR; King AM; Brown F
    J Gen Virol; 1979 Dec; 45(3):579-90. PubMed ID: 94348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioimmunoassay of influenza A virus haemagglutinin. II. Antigenic cross-reactions of influenza A (H3 subtype) viruses as determined by radioimmunoassay and haemagglutination inhibition tests.
    Russ G; Styk B; Varecková E; Mucha V; Poláková K; Blaskovic D
    Acta Virol; 1980 Jan; 24(1):12-22. PubMed ID: 6155774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of laboratory techniques for the evaluation of the antigenic potency of foot-and-mouth disease virus cultures and vaccines.
    Terpstra C; Frenkel S; Straver PJ; Barteling SJ; van Bekkum JG
    Dev Biol Stand; 1976; 35():333-42. PubMed ID: 198304
    [No Abstract]   [Full Text] [Related]  

  • 28. Development of an effective vaccine against foot-and-mouth disease with partially purified and concentrated virus antigen.
    Sen AK; Saha SN
    Acta Virol; 1994 Feb; 38(1):17-9. PubMed ID: 8067308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A thermostabile inhibitor in pig serum against foot-and-mouth disease virus. 1. Occurrence and properties determinable in vitro].
    Bögel K
    Zentralbl Veterinarmed B; 1966 Nov; 13(7):636-49. PubMed ID: 4292381
    [No Abstract]   [Full Text] [Related]  

  • 30. [Micromethod of determining the complement-binding properties of commercial series of the foot-and-mouth disease virus].
    Marchev N; Tsutsumanski V; Veleva E; Kirilov N
    Vet Med Nauki; 1978; 15(6):87-91. PubMed ID: 218334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The isoelectrofocusing technique in comparison of some Sudanese type SAT-1 foot-and-mouth disease viruses.
    Abu Elzein EM; Newman JW; Newman BJ
    Rev Elev Med Vet Pays Trop; 1989; 42(3):327-9. PubMed ID: 2562038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunology of foot-and-mouth disease in swine: experimental inactivated-virus vaccines.
    Bachrach HL; McKercher PD
    J Am Vet Med Assoc; 1972 Feb; 160(4):521-6. PubMed ID: 4337840
    [No Abstract]   [Full Text] [Related]  

  • 33. [Use of the radial immunodiffusion test in the study of foot-and-mouth disease viruses].
    Tekerlekov P
    Vet Med Nauki; 1981; 18(7):41-9. PubMed ID: 6283723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Studies on the correct quantitative relations of antigen components in mono-, bi- and trivalent foot-and-mouth disease vaccine preparations.
    Sólyom F; Czelleng F
    Dev Biol Stand; 1976; 35():289-94. PubMed ID: 198297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Preliminary study of the combination of anti-foot-and-mouth disease and anti-brucellosis vaccines].
    Mastan MB; Amighi M; Ardelan A; Bandpay MR; Ebadi A; Farsi J
    Dev Biol Stand; 1976; 35():437-43. PubMed ID: 198311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The sub-type classification of strains of foot-and-mouth disease virus.
    Forman AJ
    J Hyg (Lond); 1975 Apr; 74(2):227-32. PubMed ID: 164501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conformational alteration in foot-and-mouth disease virus virion capsid structure after complexing with monospecific antibody.
    McCullough KC; Smale CJ; Carpenter WC; Crowther JR; Brocchi E; De Simone F
    Immunology; 1987 Jan; 60(1):75-82. PubMed ID: 3028937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and characterization of monoclonal antibodies to foot and mouth disease virus type 'C'.
    Saha SN; Natarajan C
    Indian J Exp Biol; 1998 Dec; 36(12):1258-63. PubMed ID: 10093509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complement-fixation analysis of four subtypes of foot-and-mouth disease virus type A.
    Lobo CA; Cowan KM; Hanson RP
    Appl Microbiol; 1973 Oct; 26(4):570-3. PubMed ID: 4356470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Escape mutants of foot-and-mouth disease virus selected by monoclonal antibodies directed to a trypsin-sensitive neutralization epitope.
    Das BR; Pattnaik B; Venkataramanan R; Rai DV
    Acta Virol; 1997 Jun; 41(3):131-8. PubMed ID: 9385400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.